Autoantibodies against cardiac troponin I in patients presenting with myocarditis

CVD Prevention and Control

Volumn 6, Issue 2, 2011, Pages 41-46

  Matsumori, Akira ^a   Shimada, Toshio ^b   Hattori, Hiroaki ^c   Shimada, Miho ^a   Mason, Jay W ^d  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b SHIZUOKA GENERAL HOSPITAL   (Japan)

^c BML   (Japan)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Autoantibody; Cardiac troponin I; Hepatitis C virus; Myocarditis

Indexed keywords

AUTOANTIBODY; TROPONIN I;

ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HEART FAILURE; HEART MUSCLE BIOPSY; HEPATITIS C; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MYOCARDITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 79953301316     PISSN: 18754570     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvdpc.2011.02.004     Document Type: Article

References (33)

1. Rose NR. The significance of autoimmunity in myocarditis. In: Schultheiss H-P, Kappa J-F, Grötzbach G, editors. Chronic viral and inflammatory cardiomyopathy. Berlin: Springer-Varlag; 2006. p. 141-5.
2. Felix SB, Staudt A, Friedrich GB. Improvement of cardiac function after immunoadsorption in patients with dilated cardiomyopathy. Autoimmunity 2001;34:211-5. (Pubitemid 34149813)
3. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor deficient mice. Science 2001;291:319-22. (Pubitemid 32096320)
4. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003;9:1477-83. (Pubitemid 38004774)
5. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995;333:269-75.
6. Hahn EA, Hartz VL, Moon TE, O'Connell JB, Herskowitz A, McManus BM, et al. The Myocarditis Treatment Trial: design, methods and patients enrollment. Eur Heart J 1995(Suppl. O): 162-7.
7. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio Jr JJ, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987;1:3-14.
8. Ishihara M, Kujiraoka T, Iwasaki T, Nagano M, Takano M, Isuji M, et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res 2005;46:2015-22. (Pubitemid 41248499)
9. Maisch B, Deeg P, Liebau G, Kochsiek K. Diagnostic relevance of humoral and cytotoxic immune reactions in primary and secondary dilated cardiomyopathy. Am J Cardiol 1983;52:1072-8. (Pubitemid 14227665)
10. Neumann DA, Burek CL, Baughman KL, Rose NR, Herskowitz A. Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol 1990;16:839-46. (Pubitemid 20353403)
11. Konstadoulakis MM, Kroumbouzou H, Tsiamis E, Trikas A, Toutouzas P. Clinical significance of antibodies against tropomyosin, actin and myosin in patients with dilated cardiomyopathy. J Clin Lab Immunol 1993;40:61-7.
12. Caforio AL, Grazzini M, Mann JM, Keeling PJ, Bottazzo GF, McKenna WJ, et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992;85:173-1742.
13. Warraich RS, Dunn MJ, Yacoub MH. Subclass specificity of autoantibodies against myosin in patients with idiopathic dilated cardiomyopathy: pro-inflammatory antibodies in DCM patients. Biochem Biophys Res Commun 1999;259:255-61. (Pubitemid 29281219)
14. Schultheiss HP, Schulze K, Kuhl U, Ulrich G, Klingenberg M. The ADP/ATP carrier as a mitochondrial auto-antigen-facts and perspectives. Ann NY Acad Sci 1986;488:44-64.
15. Schultheiss HP, Kuhl U, Janda I, Melzner B, Ulrich G, Morad M. Antibody-mediated enhancement of calcium permeability in cardiac myocytes. J Exp Med 1988;168:2105-19. (Pubitemid 19020892)
16. Staudt A, Mobini R, Fu M, Grosse Y, Stangl V, Stangl K, et al. β(1)-Adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes. Eur J Pharmacol 2001;423:115-9.
17. Tominaga M, Matsumori A, Horie M, Yoshida H, Okada Y. Activation of Ca-permeable cation channels by myocarditis-associated antibody in guinea pig ventricular myocytes. J Clin Invest 1993;91:1231-4. (Pubitemid 23095304)
18. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000;343:1388-98.
19. Towbin JA, Bowles KR, Bowles NE. Etiologies of cardiomyopathy and heart failure. Nat Med 1999;5:266-7. (Pubitemid 29124355)
20. Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res 2005;96:144-7. (Pubitemid 40209360)
21. Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail 2006;12:293-8.
22. Matsumori A. Global alert and response network for hepatitis C virus derived heart diseases. A call to action. CVD Prev Control 2009;4:109-18.
23. Matsumori A, Shimada M, Obata T. Leukocytes are the major target of hepatitis C virus infection: Possible mechanism of multiorgan involvement including the heart. CVD Prev Control 2010;5:51-8.
24. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-42. (Pubitemid 29251016)
25. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, Coats AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997;79:1426-30.
26. Roitt IM, Brostoff J, Make D. Immunology. New York: Gower Medical Publishing; 1989, p. 2-9.
27. Riordan SM, Skinner NA, Kutovic J, Locamini S, Mclver CJ, Williams R, et al. Toll-like receptor expression in chronic hepatitic C: correlation with pro-inflammatory cytokine levels and liver injury. Inflamm Res 2006;55:279-85. (Pubitemid 44359131)
28. Latva-Hirvela J, Kyto V, Saraste A, Eriksson S, Vuorinen T, Pettersson K, et al. Development of troponin autoantibodies in experimental coxsackievirus B3 myocarditis. Eur J Clin Invest 2009;39:457-62.
29. Goser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Otti R, et al. Caediac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 2006;114:1693-702. (Pubitemid 44607117)
30. Kaya Z, Goser S, Buss SJ, Leuschner F, Otti R, Li J, et al. Identification of cardiac troponin I sequence motifs leading to heart failure by induction of myocardial inflammation and fibrosis. Circulation 2008;118:2063-72.
31. Adamczyk M, Brashear RJ, Mattingly PG. Circulating cardiac troponin-I autoantibodies in human plasma and serum. Ann NY Acad Sci 2009;1173:67-74.
32. Leuschner F, Li J, Goser S, Reinhardt L, Otti R, Bride P, et al. Absence of auto-antibodies against cardiac troponin I predicts improvement of left ventricular function after acute myocardial infarction. Eur Heart J 2008;29:1049-955.
33. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003;107: 857-63. (Pubitemid 36241044)